Posted by Michael Wonder on 28 Jan 2016
Merck announces FDA acceptance of biologics license application for bezlotoxumab, an investigational anti-toxin for prevention of clostridium difficile infection recurrence
27 January 2016 - The FDA granted priority review for bezlotoxumab, with a PDUFA action date of July 23, 2016.
For more details, go to: http://www.mercknewsroom.com/news-release/corporate-news/merck-announces-fda-acceptance-biologics-license-application-bezlotoxuma
